|
Search
Collections
Benchmarks
Upload document
Product
Trametininb
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
Aliases
once daily (QD)
1 clinical trial
1 indication
Indication
Small Cell Lung Carcinoma
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer (NSCLC).
Status: